Real-world study of PADN for pulmonary artery hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tracks how well a procedure called PADN works for people with pulmonary artery hypertension (PAH) in real-life medical settings. PADN is a minimally invasive treatment that targets nerves around the lungs to help lower blood pressure in the arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pulmonary artery hypertension (PAH).
- You received the PADN procedure in or after March 2024.
- Your doctor has confirmed you have no medical reasons that would make the procedure unsafe for you.
- You are willing to sign a consent form and allow use of your health data for research.
- You agree to follow your treatment plan and attend follow-up visits as scheduled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a procedure called pulmonary artery denervation (PADN) for people with heart failure and a certain type of high blood pressure in the lungs (pulmonary hypertension Group 2). The goal is to see if using a special device called the Gradient Denervation System can help control the high pressures and improve your symptoms.
This study tests a new procedure called pulmonary artery denervation (PADN) to lower high blood pressure in the lungs that persists after a mitral valve repair. It aims to see if this extra treatment improves symptoms and outcomes for people with this condition.
This trial tests a device that uses a catheter to deliver energy to nerves around the pulmonary arteries, aiming to reduce high blood pressure in the lungs caused by left heart failure. It is for people with ongoing heart failure symptoms despite optimal medications.
This study tests whether a gentle nerve stimulation therapy can improve symptoms and quality of life for people with moderate pulmonary arterial hypertension (PAH). It is for adults whose PAH is stable but still causes mild to moderate trouble with daily activities.
This trial looks at whether endovascular denervation (a catheter-based nerve-targeting procedure inside blood vessels) can improve symptoms and circulation in people with peripheral arterial disease (PAD). It may help if you have PAD that causes walking problems or ongoing lower-leg symptoms.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.